Mitsubishi UFJ Asset Management Co., Ltd. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
Mitsubishi UFJ Asset Management Co., Ltd. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$198,499
-21.6%
5,568
+1.4%
0.00%
-100.0%
Q2 2023$253,208
-19.2%
5,489
-29.8%
0.00%0.0%
Q1 2023$313,462
-6.3%
7,817
+6.4%
0.00%0.0%
Q4 2022$334,526
+52.8%
7,349
+39.0%
0.00%0.0%
Q3 2022$219,000
-30.5%
5,288
+0.2%
0.00%0.0%
Q2 2022$315,000
+11.3%
5,279
+35.6%
0.00%0.0%
Q1 2022$283,000
-8.4%
3,892
+6.1%
0.00%0.0%
Q4 2021$309,000
+24.6%
3,667
+33.6%
0.00%0.0%
Q3 2021$248,000
-5.3%
2,7450.0%0.00%0.0%
Q2 2021$262,000
-27.6%
2,745
-13.7%
0.00%
-50.0%
Q1 2021$362,000
+24.0%
3,180
+50.6%
0.00%0.0%
Q4 2020$292,000
+31.5%
2,112
-21.7%
0.00%0.0%
Q3 2020$222,000
+6.7%
2,698
+1.4%
0.00%0.0%
Q2 2020$208,0000.0%2,660
-43.1%
0.00%
-33.3%
Q1 2020$208,000
+26.1%
4,674
+21.8%
0.00%
+50.0%
Q4 2019$165,000
+52.8%
3,839
+51.7%
0.00%0.0%
Q3 2019$108,000
-16.3%
2,530
+24.8%
0.00%0.0%
Q2 2019$129,000
-19.4%
2,027
-12.0%
0.00%
-33.3%
Q1 2019$160,000
+107.8%
2,303
+19.7%
0.00%
+50.0%
Q4 2018$77,000
-38.9%
1,924
+16.6%
0.00%
-33.3%
Q3 2018$126,0001,6500.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2020
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 497,899$31,617,0003.20%
HIGHLINE CAPITAL MANAGEMENT, L.P. 390,453$24,794,0001.81%
First Light Asset Management, LLC 180,017$11,431,0001.59%
Rock Springs Capital Management LP 580,000$36,830,0001.33%
Capital Impact Advisors, LLC 36,165$2,244,0000.82%
SECTOR GAMMA AS 79,653$5,058,0000.81%
Verity Asset Management, Inc. 7,193$457,0000.51%
Opus Point Partners Management, LLC 5,064$322,0000.48%
Capital International Sarl 52,000$3,302,0000.46%
PACIFIC VIEW ASSET MANAGEMENT, LLC 6,216$394,0000.43%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders